ResMed Management

Management criteria checks 3/4

ResMed's CEO is Mick Farrell, appointed in Mar 2013, has a tenure of 11.75 years. total yearly compensation is $14.12M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth A$173.58M. The average tenure of the management team and the board of directors is 3.8 years and 7.1 years respectively.

Key information

Mick Farrell

Chief executive officer

US$14.1m

Total compensation

CEO salary percentage8.3%
CEO tenure11.8yrs
CEO ownership0.3%
Management average tenure3.8yrs
Board average tenure7.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mick Farrell's remuneration changed compared to ResMed's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$1b

Jun 30 2024US$14mUS$1m

US$1b

Mar 31 2024n/an/a

US$958m

Dec 31 2023n/an/a

US$890m

Sep 30 2023n/an/a

US$907m

Jun 30 2023US$14mUS$1m

US$898m

Mar 31 2023n/an/a

US$863m

Dec 31 2022n/an/a

US$809m

Sep 30 2022n/an/a

US$786m

Jun 30 2022US$12mUS$1m

US$779m

Mar 31 2022n/an/a

US$779m

Dec 31 2021n/an/a

US$522m

Sep 30 2021n/an/a

US$500m

Jun 30 2021US$10mUS$1m

US$475m

Mar 31 2021n/an/a

US$457m

Dec 31 2020n/an/a

US$699m

Sep 30 2020n/an/a

US$680m

Jun 30 2020US$10mUS$1m

US$622m

Mar 31 2020n/an/a

US$513m

Dec 31 2019n/an/a

US$455m

Sep 30 2019n/an/a

US$419m

Jun 30 2019US$10mUS$967k

US$405m

Mar 31 2019n/an/a

US$446m

Dec 31 2018n/an/a

US$450m

Sep 30 2018n/an/a

US$335m

Jun 30 2018US$9mUS$934k

US$316m

Compensation vs Market: Mick's total compensation ($USD14.12M) is above average for companies of similar size in the Australian market ($USD4.22M).

Compensation vs Earnings: Mick's compensation has been consistent with company performance over the past year.


CEO

Mick Farrell (52 yo)

11.8yrs

Tenure

US$14,120,829

Compensation

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Farrell
CEO & Chairman11.8yrsUS$14.12m0.31%
A$ 173.6m
Peter Farrell
Founderno dataUS$719.69k0.055%
A$ 30.6m
Brett Sandercock
Chief Financial Officer18.9yrsUS$3.23m0.064%
A$ 35.6m
Michael Rider
Chief Legal Officer & Secretary1.4yrsUS$2.15m0.0062%
A$ 3.5m
Justin Leong
Chief Product Officer8.6yrsUS$3.60m0.015%
A$ 8.2m
Kaushik Ghoshal
Chief Commercial Officer - SaaS2.8yrsUS$3.53m0.013%
A$ 7.3m
Alastair Robertson
Chief Information Officerless than a yearno datano data
Jim Ellis
Chief Compliance Officer6.9yrsno datano data
Yvonne-Katrin Pucknat
Chief Marketing Officer1.1yrsno datano data
Vered Keisar
Chief People Officer3.8yrsno datano data
Robert Douglas
Special Advisorless than a yearUS$6.67m0%
A$ 0
Hemanth Reddy
Chief Strategy Officer10yrsno datano data

3.8yrs

Average Tenure

57yo

Average Age

Experienced Management: RMD's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Farrell
CEO & Chairman11.8yrsUS$14.12m0.31%
A$ 173.6m
Peter Farrell
Founder35.5yrsUS$719.69k0.055%
A$ 30.6m
Richard Sulpizio
Independent Director19.3yrsUS$348.72k0.011%
A$ 6.3m
Ronald Taylor
Lead Independent Director19.9yrsUS$381.22k0.015%
A$ 8.6m
Jan De Witte
Independent Non-Executive Director5.6yrsUS$329.97k0.0046%
A$ 2.5m
Harjit Gill
Independent Director6.1yrsUS$329.97k0.0060%
A$ 3.3m
Carol Burt
Independent Director11.1yrsUS$369.97k0.011%
A$ 6.3m
Karen Drexler
Independent Director7.1yrsUS$334.97k0.0058%
A$ 3.2m
Christopher DelOrefice
Independent Directorless than a yearno datano data
Desney Tan
Independent Director3.1yrsUS$329.97k0.0026%
A$ 1.5m
John Hernandez
Independent Director3.1yrsUS$329.97k0.0020%
A$ 1.1m

7.1yrs

Average Tenure

60yo

Average Age

Experienced Board: RMD's board of directors are considered experienced (7.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 15:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ResMed Inc. is covered by 56 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterANZ Equities Pty Limited
Russell WrightAPP Securities Pty Ltd.
David RescottBaird